VGA
PSTV

Vanguard Global Advisers’s Plus Therapeutics PSTV Stock Holding History

Vanguard Global Advisers’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.3K Buy
+2,283
New +$17.3K ﹤0.01% 3487

Other funds holding PSTV

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Vanguard Global Advisers's PSTV Position: Q1 2026 in Review

Vanguard Global Advisers opened a new position in Plus Therapeutics (PSTV) in Q1 2026: 2,283 shares worth $9.3K. The stake represents ﹤0.01% of the portfolio and ranks #3487 among its holdings.

23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

  • Vanguard Global Advisers held 2,283 shares of Plus Therapeutics worth $9.3K as of Q1 2026.
  • Plus Therapeutics was a new Vanguard Global Advisers position in Q1 2026.
  • Plus Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q1 2026, its #3487 holding.
  • 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on Vanguard Global Advisers's 13F filing for Q1 2026, filed 8 May 2026.